TY - JOUR
T1 - Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients
T2 - A tissue microarray study
AU - Vrzalikova, Katerina
AU - Skarda, Joseph
AU - Ehrmann, Jiri
AU - Murray, Paul G.
AU - Fridman, Eduard
AU - Kopolovic, Jury
AU - Knizetova, Petra
AU - Hajduch, Marian
AU - Klein, Jiri
AU - Kolek, Vitezslav
AU - Radova, Lenka
AU - Kolar, Zdenek
N1 - Funding Information:
Acknowledgments This study was supported in parts from the Grant Agency for Advancement of Czech Universities (FRVS 1722/2006), Internal Grant Agency of the Ministry of Health of the Czech Republic (IGA MZ BRNR/8425-3/2005 and IGA MZ CR NR 8370-3) and Ministry of School and Education of the Czech Republic (MSM6198959216).
PY - 2008/9
Y1 - 2008/9
N2 - Purpose: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. Methods: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. Results: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10-6) and stage IV (P = 10-5) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05). Conclusions: Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.
AB - Purpose: Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. Methods: Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. Results: Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10-6) and stage IV (P = 10-5) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05). Conclusions: Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.
KW - Bmi-1 oncogene
KW - Non-small cell lung cancer
KW - Polycomb genes
KW - Tissue microarray
UR - http://www.scopus.com/inward/record.url?scp=49649083394&partnerID=8YFLogxK
U2 - 10.1007/s00432-008-0361-y
DO - 10.1007/s00432-008-0361-y
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 18264721
AN - SCOPUS:49649083394
SN - 0171-5216
VL - 134
SP - 1037
EP - 1042
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 9
ER -
